Home > Journals > Giornale Italiano di Dermatologia e Venereologia > Past Issues > Giornale Italiano di Dermatologia e Venereologia 2012 June;147(3) > Giornale Italiano di Dermatologia e Venereologia 2012 June;147(3):269-76

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA

A Journal on Dermatology and Sexually Transmitted Diseases


Official Journal of the Italian Society of Dermatology and Sexually Transmitted Diseases
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,014


eTOC

 

  AUTOIMMUNE BULLOUS DISEASES


Giornale Italiano di Dermatologia e Venereologia 2012 June;147(3):269-76

language: English

Rituximab for autoimmune blistering diseases: recent studies, new insights

Lunardon L., Payne A. S.

Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA


PDF  


Rituximab, an anti-CD20 monoclonal antibody, has been successfully used off-label for treatment of autoimmune blistering diseases. We discuss rituximab mechanisms of action, host factors that may affect response to rituximab, and the efficacy and safety of rituximab in autoimmune blistering diseases, incorporating recent data on the use of rituximab in other autoimmune disease patients.

top of page

Publication History

Cite this article as

Corresponding author e-mail

paynea@mail.med.upenn.edu